Navigation Links
ULURU Inc. Reports Financial Results for Fourth Quarter and Year Ended December 31, 2010
Date:4/1/2011

strative expenses for the fourth quarter of 2010 were $715,000, including $34,000 in share-based compensation, compared to $624,000, including $130,000 in share-based compensation, for the fourth quarter of 2009.  The increase of approximately $91,000 in selling, general and administrative expenses was due primarily to additional costs of $30,000 related to the Company's internal sales force, increased director fees of $64,000, higher legal costs of $66,000 and an accounting adjustment of $26,000 that reduced expenses in 2009.  These increases were partially offset by a decrease of $96,000 in share-based compensation.

For the year ended December 2010, selling, general and administrative expenses were $3.12 million, including $230,000 in share-based compensation, compared to $5.67 million, including $1.3 million of share-based compensation, for the same period in 2009.

The decrease of approximately $2,546,000 in selling, general and administrative expenses reflects reduced costs associated with our sales and marketing efforts of $1,182,000 due to lower head count and marketing expenses, a decrease of $1,167,000 in administrative compensation including share-based compensation, a decrease of $329,000 in legal fees as 2009 included expenses related to a proposed acquisition, lower consulting fees of $113,000, decreased legal fees related to our patents of $62,000 and lower travel expenses of $38,000.

These expense decreases were partially offset by an increase in director fees of $223,000, increased investor relation expenses of $73,000 and a commission of $30,000 related to the Aiqilin licensing agreement.

Other income and other expenses

For the year ended December 2010, interest and miscellaneous income was $10,000 as compared to $43,000 for the same period of 2009.  The decrease of $33,000 is attributable to lower cash balances and interest yields during 2010.

Interest Expense

Interest ex
'/>"/>

SOURCE ULURU Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2010 and to Provide a Business Update
2. ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®s Label Claim
3. ULURU Inc. Receives Letter of Non-Compliance From NYSE Amex
4. ULURU Inc. Announces Agreement With Exciton to Develop Antimicrobial Dressing
5. ULURU Inc. to Raise $500,000 in Registered Direct Offering
6. ULURU Inc. Reports Third Quarter 2010 Financial Results
7. ULURU Inc. Provides Altrazeal® Clinical Update
8. ULURU Inc. Announces Conference Call
9. ULURU Inc. Reports Second Quarter 2010 Financial Results
10. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
11. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 WuXi PharmaTech (Cayman) Inc. (NYSE: ... platform company serving the pharmaceutical, biotechnology, and medical device ... and the United States , today ... Tel Aviv area of Israel.  ... broad platform of integrated R&D services to local customers. ...
(Date:10/30/2014)... Boston Scientific Corporation (NYSE: BSX ... Suisse Annual Healthcare Conference on Tuesday, November 11, 2014 ... Brennan , executive vice president and chief financial officer, ... approximately 8:00 a.m. PT followed by a question and ... presentation and question and answer session will be available ...
(Date:10/30/2014)... , Oct. 30, 2014   ViaDerma, Inc. ... to bringing new products to market, has recently ... TetraStem. TetraStem is a topical liquid tetracycline-based antibiotic ... that can convert oral medication active ingredients into ... a first aid antibiotic to help prevent skin ...
Breaking Medicine Technology:WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2Boston Scientific To Participate In 2014 Credit Suisse Annual Healthcare Conference 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3
... , FRAZER, Pa., ... announced that it has filed a lawsuit in U.S. District ... of U.S. Patent Nos. 7,132,570 (the ",570 Patent"), 7,297,346 (the ... product NUVIGIL® (armodafinil) Tablets [C-IV]. Cephalon has a three-year ...
... , NEW ... market research report is available in its catalogue: , ... , http://www.reportlinker.com/p0164248/Pharmaceutical-Contract-Manufacturing---Global-Market-Trends.html ... form of increasing competition in generic markets, rising cost ...
Cached Medicine Technology:Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 2Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 3Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 4Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 2Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 3Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 4Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 5
(Date:10/30/2014)... Graphics, coding, typography and search engine optimization– ... of web design and require thorough knowledge to create ... to create a website can be as easy as ... reviews and Facebook posts all accumulate on a multiple ... evolution of how a business can develop a website," ...
(Date:10/30/2014)... 30, 2014 High efficacy and ... in the medical-grade skin care domain: Cosmederm, the ... uniquely potent topical dermatological products, today announces the ... ) with patented COSMEDERM®-7 anti-irritant technology. , ... (50% and 70%) and a low pH (pH ...
(Date:10/30/2014)... October 30, 2014 PreDiabetes Centers ... PreD Store shoppers with a supply of sugardown®, ... to reduce post-meal blood sugar spikes. Learning how to ... an important part of a diabetes prevention plan. , ... receive one complimentary tube of sugardown. The offer expires ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Radio listeners ... raising questions about the impact of traditional radio commercials ... method most likely to influence a purchasing decision. , ... of 525 consumers conducted by radio marketing company CRN ... categories, isolating the results of respondents who indicated they ...
(Date:10/30/2014)... Tara Haelle HealthDay Reporter ... More than 100 genes have been identified that appear ... And researchers say they are on their way ... contribute to the disorder. Autism spectrum disorders include ... social difficulties and repetitive behaviors. An estimated one in ...
Breaking Medicine News(10 mins):Health News:Facebook Websites In Thirty-Seconds 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3
... Study highlights:, - A blood test recently approved ... better than tests currently used in the,United States., ... mortality in these,patients, which should allow healthcare providers to ... NEW ORLEANS, Nov. 11 A new blood test,identifies ...
... NEW ORLEANS, Nov. 11 A veteran ... Association Howard L.,Lewis Achievement Award for excellence ... Stiles of Freemont, Calif., was honored for ... clinical, economic,political, ethical and cultural implications of ...
... BROOK, Ill., Nov. 11 Over $3.2 million ... days by members of the University,HealthSystem Consortium,s (UHC) ... tool. With the new, easy-to-use UHC,Interactive WorkPlan, materials ... the intuitive reports to identify, analyze, and act ...
... (NEWARK, N.J., Nov. 11, 2008) The F.M. Kirby Foundation ... of Nursing at Rutgers, The State University of New Jersey, ... New Jersey residents. , The grant will also fund the ... research and service in the best academic tradition, said Interim ...
... the treatment of erectile dysfunction and pulmonary hypertension ... of the type-5 phosphodiesterase. The type-5 phosphodiesterase is ... of sildenafil on splanchnic blood flow and portal ... led by Otto Clemmesen from Denmark addresses this ...
... Nov. 11 /PRNewswire-FirstCall/ - SXC Health Solutions Corp.,("SXC" ... SXC), a leading provider of,pharmacy benefits management services, ... the Yale Club in New York City on ... 8:00 a.m. until approximately,11:00 a.m. eastern time and ...
Cached Medicine News:Health News:New Blood Test Better Identifies Heart Failure Patients in ER 2Health News:New Blood Test Better Identifies Heart Failure Patients in ER 3Health News:New Blood Test Better Identifies Heart Failure Patients in ER 4Health News:SpendLINK(TM) Enhancements Help Academic Medical Centers Easily Track Savings Opportunities 2Health News:SXC Health Solutions to host analyst and institutional investor event 2
... is enzyme immunoassay kit for the ... concentration in serum. Enzyme immunoassay (EIA) ... many protein hormones in body fluids ... rapid and specific assay. This enzyme ...
SHIONORIA BNP,is a reagent used in the measurement of blood BNP. The blood BNP test allows accurate estimation of coronary functions....
... method for the semi-quantitative determination of ... human serum. The results of the ... an aid in the diagnosis of ... with elevated anti-neutrophil cytoplasmic antibodies (P-ANCA) ...
... The determination of Ang ... in monitoring the pharmacological effect ... variety of angiotensin converting enzyme ... II receptor antagonists as well ...
Medicine Products: